Development of a disease-specific health utility score for chronic obstructive pulmonary disease from a discrete choice experiment patient preference study

被引:0
|
作者
Jones, Byron [1 ]
Ryan, Mandy [2 ]
Cook, Nigel S. [3 ]
Gutzwiller, Florian S. [4 ]
机构
[1] Novartis Pharm AG, Patient Engagement Sci, Basel, Switzerland
[2] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland
[3] Novartis Pharm AG, Global Patient Engagement, Basel, Switzerland
[4] Novartis Pharm AG, Global Value & Access, Basel, Switzerland
关键词
disease-specific health utility score; chronic obstructive pulmonary disease; EQ-5D-3L; patient preference; DECISION-MAKING; BURDEN; EQ-5D; VOICE;
D O I
10.1017/S0266462324000242
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives While patient input to health technology assessment (HTA) has traditionally been of a qualitative nature, there is increasing interest to integrate quantitative evidence from patient preference studies into HTA decision making. Preference data can be used to generate disease-specific health utility data. We generated a health utility score for patients with chronic obstructive pulmonary disease (COPD) and consider its use within HTAs.Methods Based on qualitative research, six symptoms were identified as important to COPD patients: shortness of breath, exacerbations, chronic cough, mucus secretion, sleep disturbance, and urinary incontinence. We employed a discrete choice experiment (DCE) and the random parameter logistic regression technique to estimate utility scores for all COPD health states. The relationship between patients' COPD health utility scores, self-perceived COPD severity, and EQ-5D-3L utility scores was analyzed, with data stratified according to disease severity and comorbidity subgroups.Results The COPD health utility score had face validity, with utility scores negatively correlated with patients' self-perceived COPD severity. The correlation between the COPD health utility scores and EQ-5D-3L values was only moderate. While patient EQ-5D-3L scores were impacted by comorbidities, the COPD health utility score was less impacted by comorbid conditions.Conclusions Our COPD utility measure, derived from a DCE, provides a patient-centered health utility score and is more sensitive to the COPD health of the individual and less sensitive to other comorbidities. This disease-specific instrument should be considered alongside generic health-related quality of life instruments when valuing new COPD therapies in submissions to licensing and reimbursement agencies.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France
    Chouaid, Christos
    Germain, Nicola
    De Pouvourville, Gerard
    Aballea, Samuel
    Korchagina, Daria
    Baldwin, Michael
    Le Lay, Kate
    Luciani, Laura
    Toumi, Mondher
    Devillier, Philippe
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 785 - 792
  • [2] PATIENT PREFERENCE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INHALERS: A DISCRETE CHOICE EXPERIMENT (DCE) IN FRANCE
    Chouaid, C.
    Germain, N.
    de Pouvourville, G.
    Aballea, S.
    Korchagina, D.
    Baldwin, M.
    Le Lay, K.
    Luciani, L.
    Devillier, P.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S274 - S274
  • [3] CLINICIAN AND PATIENT TREATMENT PREFERENCES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AUSTRALIA: A DISCRETE CHOICE EXPERIMENT
    Hamrosi, K.
    Fifer, S.
    Zekan, A.
    [J]. RESPIROLOGY, 2018, 23 : 121 - 121
  • [4] Natural and disease-specific autoantibodies in chronic obstructive pulmonary disease
    Daffa, N. I.
    Tighe, P. J.
    Corne, J. M.
    Fairclough, L. C.
    Todd, I.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 180 (01): : 155 - 163
  • [5] WHAT DO PATIENTS VALUE? DEVELOPMENT OF A PREFERENCE-BASED HEALTH UTILITY SCORE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Jones, B.
    Cook, N.
    Ryan, M.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S391 - S391
  • [6] EVALUATING PATIENT PREFERENCES OF MAINTENANCE THERAPY FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UK: A DISCRETE CHOICE EXPERIMENT
    Schroeder, M.
    Lewis, H.
    Doll, H.
    Gunsoy, N. B.
    Llewellyn, S.
    Jones, P. W.
    Ismaila, A. S.
    [J]. THORAX, 2018, 73 : A232 - A232
  • [7] EVALUATING PATIENT PREFERENCES OF MAINTENANCE THERAPY FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN GERMANY: A DISCRETE CHOICE EXPERIMENT
    Lewis, H. B.
    Schroeder, M.
    Doll, H. A.
    Gunsoy, N.
    Llewellyn, S.
    Jones, P. W.
    Ismaila, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S419 - S419
  • [8] Measuring disease-specific utilities for chronic obstructive pulmonary disease health- and exacerbation profiles
    Rutten-van Molken, M.
    Hoogendoorn-Lips, M.
    Lamers, L.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A265 - A266
  • [9] Utility Estimation in Chronic Obstructive Pulmonary Disease A Preference for Change?
    Petrillo, Jennifer
    van Nooten, Floortje
    Jones, Paul
    Rutten-van Molken, Maureen
    [J]. PHARMACOECONOMICS, 2011, 29 (11) : 917 - 932
  • [10] Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
    Natalia Hawken
    Saku Torvinen
    Mohamed-Elmoctar Neine
    Ikbel Amri
    Mondher Toumi
    Samuel Aballéa
    Adam Plich
    Nicolas Roche
    [J]. BMC Pulmonary Medicine, 17